Candel Therapeutics, Inc. (CADL) key performance indicators and operating metrics (4 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Prostate Cancer Recurrence or Death Risk Reduction | 30.00 percent | FY2025-Q1 |
| Pathological Complete Response Rate Two-Year Post-Treatment Biopsies for CAN-2409 Plus Valacyclovir | 80.40 percent | FY2025-Q1 |
| Pathological Complete Response Rate Two-Year Post-Treatment Biopsies for Control Arm | 63.60 percent | FY2025-Q1 |
| Disease-Free Survival Intent-To-Treat Population Size for CAN-2409 Plus Valacyclovir and Standard of Care | 496.00 | FY2025-Q1 |
Back to CADL overview · CADL earnings · CADL holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.